Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Australia's Telix Pharmaceuticals jumps after Jefferies hikes PT

(Updates share moves)
    ** Shares of Telix Pharmaceuticals  TLX.AX  rise 7.2% to
A$18.44, set for best day since May 31, if gains hold
    ** Analysts at Jefferies see meaningful upside for TLX
should its products be approved
    ** Brokerage upgrades price target to A$20.70/shr from
A$15.30, maintains "buy" rating
    ** Jefferies assumes a successful New Drug Application for
TLX's potential new prostate cancer diagnostic
    ** A successful new drug application may allow TLX to sell a
second-generation Illuccix in the U.S., and hence retain the
higher-priced pass-through status Illuccix currently has -
Jefferies
    ** All eight analysts covering the stock rate "Buy" or
higher; their median PT is A$19.00 - LSEG data
    ** Stock has risen 70.6% YTD, as of last close

 (Reporting by Shivangi Lahiri and Ayushman Ojha in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))

Recent news on Trans Lux

See all news